[1]
|
O’Neill, R.E. and Cao, X. (2019) Co-Stimulatory and Co-Inhibitory Pathways in Cancer Immunotherapy. Advances in Cancer Research, 143, 145-194. https://doi.org/10.1016/bs.acr.2019.03.003
|
[2]
|
Salmaninejad, A., Valilou, S.F., Shabgah, A.G., et al. (2019) PD-1/PD-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy. Journal of Cel-lular Physiology, 234, 16824-16837. https://doi.org/10.1002/jcp.28358
|
[3]
|
Baumeister, S.H., Freeman, G.J., Dranoff, G., et al. (2016) Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 34, 539-573. https://doi.org/10.1146/annurev-immunol-032414-112049
|
[4]
|
Hosseini, A., Gharibi, T., Marofi, F., et al. (2020) CTLA-4: From Mechanism to Autoimmune Therapy. International Immunopharmacology, 80, Article ID: 106221. https://doi.org/10.1016/j.intimp.2020.106221
|
[5]
|
Wei, S.C., Duffy, C.R. and Allison, J.P. (2018) Fun-damental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. https://doi.org/10.1158/2159-8290.CD-18-0367
|
[6]
|
Hargadon, K.M., Johnson, C.E. and Williams, C.J. (2018) Immune Checkpoint Blockade Therapy for Cancer: An Overview of FDA-Approved Immune Checkpoint Inhibitors. In-ternational Immunopharmacology, 62, 29-39.
https://doi.org/10.1016/j.intimp.2018.06.001
|
[7]
|
Chen, R., Ganesan, A., Okoye, I., et al. (2020) Targeting B7-1 in Immunotherapy. Medicinal Research Reviews, 40, 654-682. https://doi.org/10.1002/med.21632
|
[8]
|
Pentcheva-Hoang, T., Egen, J.G., Wojnoonski, K., et al. (2004) B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse. Immunity, 21, 401-413. https://doi.org/10.1016/j.immuni.2004.06.017
|
[9]
|
Rowshanravan, B., Halliday, N. and Sansom, D.M. (2018) CTLA-4: A Moving Target in Immunotherapy. Blood, 131, 58-67. https://doi.org/10.1182/blood-2017-06-741033
|
[10]
|
Hui, E., Cheung, J., Zhu, J., et al. (2017) T Cell Costimulatory Receptor CD28 Is a Primary Target for PD-1-Mediated Inhibition. Science, 355, 1428-1433. https://doi.org/10.1101/086652
|
[11]
|
Kamphorst, A.O., Wieland, A., Nasti, T., et al. (2017) Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies Is CD28-Dependent. Science, 355, 1423-1427. https://doi.org/10.1126/science.aaf0683
|
[12]
|
Bhatia, A. and Kumar, Y. (2014) Cellular and Molecular Mechanisms in Cancer Immune Escape: A Comprehensive Review. Expert Review of Clinical Immunology, 10, 41-62. https://doi.org/10.1586/1744666X.2014.865519
|
[13]
|
Demaria, O., Cornen, S., Daeron, M., et al. (2019) Harness-ing Innate Immunity in Cancer Therapy. Nature, 574, 45-56.
https://doi.org/10.1038/s41586-019-1593-5
|
[14]
|
Yang, Y. (2015) Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer. Journal of Clinical Investigation, 125, 3335-3337. https://doi.org/10.1172/JCI83871
|
[15]
|
Winograd, R., Byrne, K.T., Evans, R.A., et al. (2015) Induction of T-Cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carci-noma. Cancer Immunology Research, 3, 399-411. https://doi.org/10.1158/2326-6066.CIR-14-0215
|
[16]
|
Kennedy, L.B. and Salama, A.K.S. (2020) A Review of Cancer Immunotherapy Toxicity. CA: A Cancer Journal for Clinicians, 70, 86-104. https://doi.org/10.3322/caac.21596
|
[17]
|
Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, 38. https://doi.org/10.1038/s41572-020-0160-6
|
[18]
|
Liu, Y.H., Zang, X.Y., Wang, J.C., et al. (2019) Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomedicine & Pharmacotherapy, 120, Article ID: 109437.
https://doi.org/10.1016/j.biopha.2019.109437
|
[19]
|
Weber, J.S., Postow, M., Lao, C.D., et al. (2016) Management of Adverse Events Following Treatment with Anti-Programmed Death-1 Agents. Oncologist, 21, 1230-1240. https://doi.org/10.1634/theoncologist.2016-0055
|
[20]
|
Darnell, E.P., Mooradian, M.J., Baruch, E.N., et al. (2020) Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 22, 39. https://doi.org/10.1007/s11912-020-0897-9
|
[21]
|
Friedman, C.F., Proverbs-Singh, T.A. and Postow, M.A. (2016) Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncology, 2, 1346-1353.
https://doi.org/10.1001/jamaoncol.2016.1051
|
[22]
|
Das, S. and Johnson, D.B. (2019) Immune-Related Adverse Events and Anti-Tumor Efficacy of Immune Checkpoint Inhibitors. Journal for ImmunoTherapy of Cancer, 7, 306. https://doi.org/10.1186/s40425-019-0805-8
|
[23]
|
Sugano, T., Seike, M., Saito, Y., et al. (2020) Immune Check-point Inhibitor-Associated Interstitial Lung Diseases Correlate with Better Prognosis in Patients with Advanced Non-Small-Cell Lung Cancer. Thoracic Cancer, 11, 1052-1060. https://doi.org/10.1111/1759-7714.13364
|
[24]
|
Shankar, B., Zhang, J., Naqash, A.R., et al. (2020) Multisystem Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncology, 6, 1952-1956.
https://doi.org/10.1001/jamaoncol.2020.5012
|
[25]
|
Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
https://doi.org/10.1016/j.ejca.2008.10.026
|
[26]
|
Wang, P.F., Chen, Y., Song, S.Y., et al. (2017) Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Frontiers in Phar-macology, 8, Article No. 730.
https://doi.org/10.3389/fphar.2017.00730
|
[27]
|
Xu, C., Chen, Y.P., Du, X.J., et al. (2018) Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis. British Medical Journal, 363, k4226. https://doi.org/10.1136/bmj.k4226
|
[28]
|
Ja, L.G. and Sher, A. (2020) Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. Cancer Investigation, 38, 365-371.
https://doi.org/10.1080/07357907.2020.1783677
|
[29]
|
Khoja, L., Day, D., Chen, T.W.W., et al. (2017) Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28, 2377-2385. https://doi.org/10.1093/annonc/mdx286
|
[30]
|
Rogado, J., Sanchez-Torres, J.M., Romero-Laorden, N., et al. (2019) Immune-Related Adverse Events Predict the Therapeutic Efficacy of Anti-PD-1 Antibodies in Cancer Patients. European Journal of Cancer, 109, 21-27.
https://doi.org/10.1016/j.ejca.2018.10.014
|
[31]
|
Akamatsu, H., Murakami, E., Oyanagi, J., et al. (2020) Im-mune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Re-sponders with Advanced Non-Small Cell Lung Cancer. Oncologist, 25, e679-e683. https://doi.org/10.1634/theoncologist.2019-0299
|
[32]
|
Robert, C., Hwu, W.J., Hamid, O., et al. (2021) Long-Term Safety of Pembrolizumab Monotherapy and Relationship with Clinical Outcome: A Landmark Analysis in Patients with Advanced Melanoma. European Journal of Cancer, 144, 182-191. https://doi.org/10.1016/j.ejca.2020.11.010
|
[33]
|
Robert, C., Ribas, A., Wolchok, J.D., et al. (2014) An-ti-Programmed-Death-Receptor-1 Treatment with Pembrolizumab in Ipilimumab-Refractory Advanced Melanoma: A Randomised Dose-Comparison Cohort of a Phase 1 Trial. The Lancet, 384, 1109-1117. https://doi.org/10.1016/S0140-6736(14)60958-2
|
[34]
|
Ribas, A., Puzanov, I., Dummer, R., et al. (2015) Pem-brolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): A Ran-domised, Controlled, Phase 2 Trial. The Lancet Oncology, 16, 908-918. https://doi.org/10.1016/S1470-2045(15)00083-2
|
[35]
|
Schachter, J., Ribas, A., Long, G.V., et al. (2017) Pem-brolizumab versus Ipilimumab for Advanced Melanoma: Final Overall Survival Results of a Multicentre, Randomised, Open-Label Phase 3 Study (KEYNOTE-006). The Lancet, 390, 1853-1862. https://doi.org/10.1016/S0140-6736(17)31601-X
|
[36]
|
Ng, K.Y.Y., Tan, S.H., Tan, J.J.E., et al. (2022) Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 11, 9-21.
https://doi.org/10.1159/000518619
|
[37]
|
Hussaini, S., Chehade, R., Boldt, R.G., et al. (2021) Association between Immune-Related Side Effects and Efficacy and Benefit of Immune Checkpoint Inhibitors—A Systematic Review and Meta-Analysis. Cancer Treatment Reviews, 92, Article ID: 102134. https://doi.org/10.1016/j.ctrv.2020.102134
|
[38]
|
Khan, S. and Gerber, D.E. (2020) Autoimmunity, Checkpoint In-hibitor Therapy and Immune-Related Adverse Events: A Review. Seminars in Cancer Biology, 64, 93-101. https://doi.org/10.1016/j.semcancer.2019.06.012
|
[39]
|
Haanen, J., Carbonnel, F., Robert, C., et al. (2017) Man-agement of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 28, iv119-iv142.
https://doi.org/10.1093/annonc/mdx225
|
[40]
|
Teufel, A., Zhan, T., Hartel, N., et al. (2019) Management of Immune Related Adverse Events Induced by Immune Checkpoint Inhibition. Cancer Letters, 456, 80-87. https://doi.org/10.1016/j.canlet.2019.04.018
|
[41]
|
Reck, M., Mok, T.S.K., Nishio, M., et al. (2019) Atezolizumab Plus Bevacizumab and Chemotherapy in Non-Small- Cell Lung Cancer (IMpower150): Key Subgroup Analyses of Pa-tients with EGFR Mutations or Baseline Liver Metastases in a Randomised, Open-Label Phase 3 Trial. The Lancet Res-piratory Medicine, 7, 387-401.
https://doi.org/10.1016/S2213-2600(19)30084-0
|
[42]
|
West, H., Mccleod, M., Hussein, M., et al. (2019) Atezoli-zumab in Combination with Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Ran-domised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 924-937.
https://doi.org/10.1016/S1470-2045(19)30167-6
|
[43]
|
Nishio, M., Barlesi, F., West, H., et al. (2021) Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results from the Randomized Phase 3 IMpow-er132 Trial. Journal of Thoracic Oncology, 16, 653-664. https://doi.org/10.1016/j.jtho.2020.11.025
|
[44]
|
Lee, P.Y., Oen, K.Q.X., Lim, G.R.S., et al. (2021) Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Ad-verse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. Cancers, 13, Article No. 1308. https://doi.org/10.3390/cancers13061308
|
[45]
|
Peng, L., Wang, Y., Liu, F., et al. (2020) Peripheral Blood Markers Predictive of Outcome and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors. Cancer Immunology, Immunotherapy, 69, 1813-1822. https://doi.org/10.1007/s00262-020-02585-w
|
[46]
|
Kos, F.T., Hocazade, C., Kos, M., et al. (2015) Assessment of Prognostic Value of “Neutrophil to Lymphocyte Ratio” and “Prognostic Nutritional Index” as a Sytemic Inflammatory Marker in Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 16, 3997-4002. https://doi.org/10.7314/APJCP.2015.16.9.3997
|
[47]
|
Miyazaki, T., Sakai, M., Sohda, M., et al. (2016) Prognostic Significance of Inflammatory and Nutritional Parameters in Patients with Esophageal Cancer. Anticancer Research, 36, 6557-6562. https://doi.org/10.21873/anticanres.11259
|
[48]
|
Thompson, J.A., Schneider, B.J., Brahmer, J., et al. (2020) NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18, 230-241.
https://doi.org/10.6004/jnccn.2020.0012
|
[49]
|
Haanen, J., Carbonnel, F., Robert, C., et al. (2018) Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29, iv264-iv266. https://doi.org/10.1093/annonc/mdy162
|
[50]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statis-tics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Can-cer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[51]
|
Kalemkerian, G.P., Loo, B.W., Akerley, W., et al. (2018) NCCN Guide-lines Insights: Small Cell Lung Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network, 16, 1171-1182.
https://doi.org/10.6004/jnccn.2018.0079
|
[52]
|
Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 19, 254-266.
|
[53]
|
Antonia, S.J., López-Martin, J.A., Bendell, J., et al. (2016) Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, 883-895. https://doi.org/10.1016/S1470-2045(16)30098-5
|
[54]
|
Spigel, D.R., Vicente, D., Ciuleanu, T.E., et al. (2021) Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. Annals of Oncology, 32, 631-641. https://doi.org/10.1016/j.annonc.2021.01.071
|
[55]
|
Owonikoko, T.K., Park, K., Govindan, R., et al. (2021) Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39, 1349-1359.
|
[56]
|
Chung, H.C., Piha-Paul, S.A., Lopez-Martin, J., et al. (2020) Pembrolizumab after Two or More Lines of Previous Therapy in Patients with Recurrent or Metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 15, 618-627. https://doi.org/10.1016/j.jtho.2019.12.109
|
[57]
|
Rudin, C.M., Awad, M.M., Navarro, A., et al. (2020) Pembroli-zumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Ran-domized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 2369-2379.
|
[58]
|
Zhou, Y., Chen, C., Zhang, X., et al. (2018) Immune-Checkpoint In-hibitor Plus Chemotherapy versus Conventional Chemotherapy for First-Line Treatment in Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Journal for ImmunoTherapy of Cancer, 6, 155. https://doi.org/10.1186/s40425-018-0477-9
|
[59]
|
O’Donnell, J.S., Hoefsmit, E.P., Smyth, M.J., et al. (2019) The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clinical Cancer Research, 25, 5743-5751. https://doi.org/10.1158/1078-0432.CCR-18-2641
|
[60]
|
Topalian, S.L., Taube, J.M. and Pardoll, D.M. (2020) Ne-oadjuvant Checkpoint Blockade for Cancer Immunotherapy. Science, 367, eaax0182. https://doi.org/10.1126/science.aax0182
|
[61]
|
Landre, T., Des Guetz, G., Chouahnia, K., et al. (2020) Immune Checkpoint Inhibitors for Patients Aged ≥75 Years with Advanced Cancer in First- and Second-Line Settings: A Me-ta-Analysis. Drugs & Aging, 37, 747-754.
https://doi.org/10.1007/s40266-020-00788-5
|
[62]
|
Liu, J., Blake, S.J., Yong, M.C., et al. (2016) Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discovery, 6, 1382-1399. https://doi.org/10.1158/2159-8290.CD-16-0577
|
[63]
|
Provencio, M., Nadal, E., Insa, A., et al. (2020) Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1413-1422. https://doi.org/10.1016/S1470-2045(20)30453-8
|
[64]
|
Kalemkerian, G.P., Narula, N., Kennedy, E.B., et al. (2018) Molecular Testing Guideline for the Selection of Patients with Lung Cancer for Treatment with Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36, 911-919.
|
[65]
|
Park, K., Vansteenkiste, J., Lee, K.H., et al. (2020) Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Locally-Advanced Unresectable Non-Small-Cell Lung Cancer: A KSMO-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Annals of Oncology, 31, 191-201.
https://doi.org/10.1016/j.annonc.2019.10.026
|
[66]
|
Garcia, J., Hurwitz, H.I., Sandler, A.B., et al. (2020) Bevaci-zumab (Avastin®) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook. Cancer Treatment Reviews, 86, Article ID: 102017.
https://doi.org/10.1016/j.ctrv.2020.102017
|
[67]
|
Assoun, S., Brosseau, S., Steinmetz, C., et al. (2017) Bevaci-zumab in Advanced Lung Cancer: State of the Art. Future Oncology, 13, 2515-2535. https://doi.org/10.2217/fon-2017-0302
|
[68]
|
Abdollahi, A., Hlatky, L. and Huber, P.E. (2005) Endostatin: The Logic of Antiangiogenic Therapy. Drug Resistance Updates, 8, 59-74. https://doi.org/10.1016/j.drup.2005.03.001
|
[69]
|
Folkman, J. (2006) Antiangiogenesis in Cancer Thera-py—Endostatin and Its Mechanisms of Action. Experimental Cell Research, 312, 594-607. https://doi.org/10.1016/j.yexcr.2005.11.015
|
[70]
|
Poluzzi, C., Iozzo, R.V. and Schaefer, L. (2016) Endostatin and Endorepellin: A Common Route of Action for Similar Angiostatic Cancer Avengers. Advanced Drug Delivery Reviews, 97, 156-173.
https://doi.org/10.1016/j.addr.2015.10.012
|
[71]
|
Montanino, A., Manzo, A., Carillio, G., et al. (2021) Angiogene-sis Inhibitors in Small Cell Lung Cancer. Frontiers in Oncology, 11, Article ID: 655316.
|
[72]
|
Sun, Y., Wang, J.W., Liu, Y.Y., et al. (2013) Long-Term Results of a Randomized, Double-Blind, and Placebo-Controlled Phase III Trial: Endostar (rh-Endostatin) versus Placebo in Combination with Vinorelbine and Cisplatin in Advanced Non-Small Cell Lung Cancer. Thoracic Cancer, 4, 440-448. https://doi.org/10.1111/1759-7714.12050
|
[73]
|
Li, Y., Yi, Y., Lin, A., et al. (2020) A Comparison of the Efficacy of Antiangiogenic Agents Combined with Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis. Cancer Cell International, 20, 548. https://doi.org/10.1186/s12935-020-01639-4
|
[74]
|
Wang, P.L., Fang, X.Z., Yin, T.W., et al. (2021) Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients with Advanced Non-Small-Cell Lung Cancer after Previous Systemic Treatment Failure—A Retrospective Study. Frontiers in Oncology, 11, Article ID: 628124. https://doi.org/10.3389/fonc.2021.628124
|
[75]
|
Proto, C., Ferrara, R., Signorelli, D., et al. (2019) Choosing Wisely First Line Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): What to Add and What to Leave out. Cancer Treatment Reviews, 75, 39-51.
https://doi.org/10.1016/j.ctrv.2019.03.004
|
[76]
|
Arneth, B. (2019) Tumor Microenvironment. Medicina, 56, Article No. 15. https://doi.org/10.3390/medicina56010015
|
[77]
|
Vitale, I., Manic, G., Coussens, L.M., et al. (2019) Mac-rophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 30, 36-50. https://doi.org/10.1016/j.cmet.2019.06.001
|
[78]
|
Denton, A.E., Roberts, E.W. and Fearon. D.T. (2018) Stromal Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 1060, 99-114. https://doi.org/10.1007/978-3-319-78127-3_6
|
[79]
|
Labani-Motlagh, A., Ashja-Mahdavi, M. and Loskog, A. (2020) The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Frontiers in Immunology, 11, Article No. 940.
https://doi.org/10.3389/fimmu.2020.00940
|
[80]
|
Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Can-cer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. https://doi.org/10.1016/j.immuni.2019.06.025
|
[81]
|
Lim, A.R., Rathmell, W.K. and Rathmell, J.C. (2020) The Tu-mor Microenvironment as a Metabolic Barrier to Effector T Cells and Immunotherapy. eLife, 9, e55185. https://doi.org/10.7554/eLife.55185
|
[82]
|
Binnewies, M., Roberts, E.W., Kersten, K., et al. (2018) Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nature Medicine, 24, 541-550. https://doi.org/10.1038/s41591-018-0014-x
|
[83]
|
Shi, R., Liao, C.H. and Zhang, Q. (2021) Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications. Cells, 10, Article No. 678. https://doi.org/10.3390/cells10030678
|
[84]
|
Boedtkjer, E. and Pedersen, S.F. (2020) The Acidic Tumor Microen-vironment as a Driver of Cancer. Annual Review of Physiology, 82, 103-126. https://doi.org/10.1146/annurev-physiol-021119-034627
|
[85]
|
Estrella, V., Chen, T., Lloyd, M., et al. (2013) Acid-ity Generated by the Tumor Microenvironment Drives Local Invasion. Cancer Research, 73, 1524-1535. https://doi.org/10.1158/0008-5472.CAN-12-2796
|
[86]
|
Nakamura, K. and Smyth, M.J. (2017) Targeting Can-cer-Related Inflammation in the Era of Immunotherapy. Immunology & Cell Biology, 95, 325-332. https://doi.org/10.1038/icb.2016.126
|
[87]
|
Shimizu, K., Iyoda, T., Okada, M., et al. (2018) Immune Suppression and Reversal of the Suppressive Tumor Microenvironment. International Immunology, 30, 445-454. https://doi.org/10.1093/intimm/dxy042
|
[88]
|
Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in Cancer and Other Diseases. Nature: International Weekly Journal of Science, 407, 249-257. https://doi.org/10.1038/35025220
|
[89]
|
Schito, L. and Semenza, G.L. (2016) Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. Trends in Cancer, 2, 758-770. https://doi.org/10.1016/j.trecan.2016.10.016
|
[90]
|
Fukumura, D., Kloepper, J., Amoozgar, Z., et al. (2018) En-hancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges. Nature Reviews Clinical Oncolo-gy, 15, 325-340.
https://doi.org/10.1038/nrclinonc.2018.29
|
[91]
|
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., et al. (2017) Dual Angiopoietin-2 and VEGFA Inhibition Elicits Antitumor Immunity that Is Enhanced by PD-1 Checkpoint Blockade. Science Translational Medicine, 9.
https://doi.org/10.1126/scitranslmed.aak9670
|
[92]
|
Yasuda, S., Sho, M., Yamato, I., et al. (2013) Simultaneous Blockade of Programmed Death 1 and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Induces Synergistic Anti-Tumour Effect in Vivo. Clinical & Experimental Immunology, 172, 500-506. https://doi.org/10.1111/cei.12069
|
[93]
|
Wu, F.T.H., Xu, P., Chow, A., et al. (2019) Pre- and Post-Operative an-ti-PD-L1 Plus Anti-Angiogenic Therapies in Mouse Breast Or Renal Cancer Models of Micro- or Macro-Metastatic Disease. British Journal of Cancer, 120, 196-206. https://doi.org/10.1038/s41416-018-0297-1
|
[94]
|
Wang, Q., Gao, J., Di, W., et al. (2020) Anti-Angiogenesis Therapy Overcomes the Innate Resistance to PD-1/PD-L1 Blockade in VEGFA-Overexpressed Mouse Tumor Models. Cancer Immunology, Immunotherapy, 69, 1781-1799.
https://doi.org/10.1007/s00262-020-02576-x
|
[95]
|
Jain, R.K. (2014) Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 26, 605-622. https://doi.org/10.1016/j.ccell.2014.10.006
|
[96]
|
Yi, M., Jiao, D., Qin, S., et al. (2019) Synergistic Effect of Im-mune Checkpoint Blockade and Anti-Angiogenesis in Cancer Treatment. Molecular Cancer, 18, Article No. 60. https://doi.org/10.1186/s12943-019-0974-6
|
[97]
|
Mcdermott, D.F., Huseni, M.A., Atkins, M.B., et al. (2018) Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab versus Sunitinib in Renal Cell Carcinoma. Nature Medicine, 24, 749-757. https://doi.org/10.1038/s41591-018-0053-3
|
[98]
|
Rini, B.I., Powles, T., Atkins, M.B., et al. (2019) Atezolizumab Plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmo-tion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial. The Lancet, 393, 2404-2415. https://doi.org/10.1016/S0140-6736(19)30723-8
|
[99]
|
Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[100]
|
Lee, M.S., Ryoo, B.Y., Hsu, C.H., et al. (2020) Atezolizumab with or without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-Label, Multicentre, Phase 1b Study. The Lancet Oncology, 21, 808-820.
https://doi.org/10.1016/S1470-2045(20)30156-X
|